XELJANZ® (tofacitinib citrate) delivered significant results versus placebo, even in more challenging patients with prior TNFi treatment failure1
XELJANZ® (tofacitinib citrate) significantly improved the Mayo scores in more patients who failed prior TNFi therapy versus placebo at Week 521,2
Data From the OCTAVE Sustain Maintenance Study: TNFi-failure Patients Only1,2
Adapted from Sandborn WJ, et al. 2017.
*Remission was defined as a Mayo score of ≤2 with no individual subscore of >1 and rectal bleeding subscore of 0.3
†Improvement of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).3 To limit potential bias, evaluation of endoscopies was conducted by readers who were blinded to treatment (XELJANZ® [tofacitinib citrate] or placebo) and had no contact with patients, investigators or other individuals involved in the study.1-3
‡Sustained steroid-free remission was defined as being in remission and on no corticosteroids for at least 4 weeks prior to the visit at both Weeks 24 and 52 among those in remission at maintenance baseline.1
The recommended dose is 10 mg given orally BID for induction for 8 weeks.
The recommended dose for the maintenance treatment is XELJANZ® (tofacitinib citrate) 5 mg given orally BID.4
Example
Example
Example
BID, twice daily; OCTAVE, Operationally Critical Threat, Asset and Vulnerability Evaluation; TNFi, tumour necrosis factor inhibitor.
References:
Dosing & Administration
Helps protect against RA, PsA and UC
Review the upcoming events
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.